Daewoong Pharamceutical Co., Ltd.、Beijing Daewoong Pharamceutical R&D Center Co., Ltd.：

Please note that on October 18th, 2024, CFDI sent the Notification of Drug Oversea Inspection results of Botulinum Toxin Type A for Injection to Beijing Daewoong Pharamceutical R&D Center Co., Ltd., the agency of the medicine in China.

If there are any questions, please do not hesitate to contact us as soon.

Contact: Yang Jingpeng

Tel.86-010-68441631

Center for Food and Drug Inspection of NMPA      

October 18, 2024